Kemnay Advisory Services’s Viridian Therapeutics VRDN Stock Holding History

Kemnay Advisory Services’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.5K	Buy	+792	New	+$23.5K	﹤0.01%	830

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Kemnay Advisory Services's VRDN Position: Q1 2026 in Review

Kemnay Advisory Services opened a new position in Viridian Therapeutics (VRDN) in Q1 2026: 792 shares worth $15.5K. The stake represents ﹤0.01% of the portfolio and ranks #830 among its holdings.

225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Kemnay Advisory Services held 792 shares of Viridian Therapeutics worth $15.5K as of Q1 2026.
Viridian Therapeutics was a new Kemnay Advisory Services position in Q1 2026.
Viridian Therapeutics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #830 holding.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.